The short version of immunomodulation fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Thymosin alpha-1 is a short peptide of 28 amino acid residues first described in the 1970s as a component of thymic extracts. Its N-terminal residue carries an acetyl group, and the sequence is highly conserved across mammalian species. The peptide is not encoded as a standalone gene product; it is released by proteolytic cleavage from the N-terminus of prothymosin alpha, a larger acidic nuclear protein. That precursor relationship places it within a broader family of thymic and immune-associated peptides that have been studied for decades.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
| Property | Value | Notes |
|---|---|---|
| Residue count | 28 amino acids | Acetyl group on the first residue |
| Approximate molecular mass | 3108 daltons | Calculated from the consensus sequence |
| Origin | Cleavage product of prothymosin alpha | Not encoded as a separate gene product |
| Primary research focus | Immune modulation | Studied in viral hepatitis and as a vaccine adjuvant |
| Common synonyms | Thymalfasin, Tα1, thymosin alpha 1 | Thymalfasin is the assigned nonproprietary name |
Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α4β7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), blocking the α4β7 integrin results in gut-selective anti-inflammatory activity.
=== FDA Warning === On February 12, 2007, after an advisory committee discussion and vote in December 2006, the FDA announced a revision to the labeling of Ketek. The changes included the removal of two of the three previously approved indications: acute bacterial sinusitis and acute bacterial exacerbations of chronic bronchitis. The agency determined that the balance of benefits and risks no longer supported approval of the drug for these indications. Ketek remained on the market for the treatment of community acquired bacterial pneumonia of mild to moderate severity (acquired outside of hospitals or long-term care facilities). In addition, the FDA worked with the manufacturer to update the product labeling with a "black box warning," their strongest form of warning. Ketek's warning states that it should not be used in patients with myasthenia gravis, a disease that causes muscle weakness. Following this decision, Sanofi-Aventis withdrew the drug from active sales in the United States.
The vaginal cuff is the upper portion of the vagina that opens up into the peritoneum and is sutured shut after the removal of the cervix and uterus during a hysterectomy. The vaginal cuff is created by suturing together the edges of the surgical site where the cervix was attached to the vagina. This is accomplished by bringing the edges of the vagina together and suturing them together and to the uterosacral ligaments to prevent prolapse. The peritoneum is also sewn into the newly created vaginal cuff. There may be an advantage to using one method of closure over another. The vaginal cuff has a tendency to partially or completely dehisce or open up. A further complication that can accompany the dehiscence of the vaginal cuff is evisceration or the movement of intestines into the vagina. Some or all of the vaginal cuff can reopen. The risk of vaginal cuff complications is related to the approach to hysterectomy: robotic-assisted total laparoscopic hysterectomy, total laparoscopic hysterectomy, laparoscopic-assisted vaginal hysterectomy, total abdominal hysterectomy, and total vaginal hysterectomy. The vaginal cuff can be stressed by sexual intercourse, chronic constipation, asthma, COPD, and other actions that increase intra-abdominal pressure. This structure is prone to infection, hematoma and other postoperative complications. Factors that are thought to affect wound healing are radiation treatments, age, pelvic organ prolapse, the use of corticosteroids, concurrent malignancy.
FBGC's will also begin to produce reactive oxygen intermediates, enzymes for degradation, and acid between their cell membranes and the surface of the biomaterial. The composition of the biomaterial will determine how compatible and durable it is in the body. If too much damage occurs due to the chemicals that are produced, the biomaterial may fail and have to be replaced.
== History == The existence of a compensatory mechanism for telomere shortening was first found by Soviet biologist Alexey Olovnikov in 1973, who also suggested the telomere hypothesis of aging and the telomere's connections to cancer and perhaps some neurodegenerative diseases. Telomerase in the ciliate Tetrahymena was discovered by Carol W. Greider and Elizabeth Blackburn in 1984. Together with Jack W. Szostak, Greider and Blackburn were awarded the 2009 Nobel Prize in Physiology or Medicine for their discovery. Later the cryo-EM structure of telomerase was first reported in T. thermophila, to be followed a few years later by the cryo-EM structure of telomerase in humans. The role of telomeres and telomerase in cell aging and cancer was established by scientists at biotechnology company Geron with the cloning of the RNA and catalytic components of human telomerase and the development of a polymerase chain reaction (PCR) based assay for telomerase activity called the TRAP assay, which surveys telomerase activity in multiple types of cancer. The negative stain electron microscopy (EM) structures of human and Tetrahymena telomerases were characterized in 2013. Two years later, the first cryo-electron microscopy (cryo-EM) structure of telomerase holoenzyme (Tetrahymena) was determined. In 2018, the structure of human telomerase was determined through cryo-EM by UC Berkeley scientists.
Sources: en.wikipedia.org
History of chemical physics – history of the branch of physics that studies chemical processes from the point of view of physics and engineering. History of oenology – history of the science and study of all aspects of wine and winemaking except vine-growing and grape-harvesting, which is a subfield called viticulture. History of spectroscopy – history of the study of the interaction between matter and radiated energy History of surface science – history of the study of physical and chemical phenomena that occur at the interface of two phases, including solid–liquid interfaces, solid–gas interfaces, solid–vacuum interfaces, and liquid–gas interfaces. History of chemicals History of chemical elements - The concept of an "element" as an indivisible substance has developed through three major historical phases: Classical definitions (such as those of the ancient Greeks), chemical definitions, and atomic definitions. History of carbon History of hydrogen Timeline of hydrogen technologies History of oxygen History of chemical products History of aspirin History of cosmetics History of gunpowder History of pharmaceutical drugs History of vitamins History of chemical processes History of manufactured gas History of the Haber process History of the chemical industry History of the petroleum industry History of the pharmaceutical industry History of the periodic table
== Other uses == The ground product can be called masa nixtamalera. In Central American and Mexican cuisine, masa nixtamalera is cooked with water and milk to make a thick, gruel-like beverage called atole. When made with chocolate and sugar, it becomes atole de chocolate. Adding anise and piloncillo to this mixture creates champurrado, a popular breakfast drink.
=== Phase III - further modification and excretion === After phase II reactions, the xenobiotic conjugates may be further metabolised. A common example is the processing of glutathione conjugates to acetylcysteine (mercapturic acid) conjugates. Here, the γ-glutamate and glycine residues in the glutathione molecule are removed by Gamma-glutamyl transpeptidase and dipeptidases. In the final step, the cystine residue in the conjugate is acetylated. Conjugates and their metabolites can be excreted from cells in phase III of their metabolism, with the anionic groups acting as affinity tags for a variety of membrane transporters of the multidrug resistance protein (MRP) family. These proteins are members of the family of ATP-binding cassette transporters and can catalyse the ATP-dependent transport of a huge variety of hydrophobic anions, and thus act to remove phase II products to the extracellular medium, where they may be further metabolised or excreted.
The GABA transporter 1 (GAT-1) and GABA reuptake inhibitor tiagabine (Gabitril) is approved and clinically used as an anticonvulsant. It has also been used off-label in the treatment of anxiety disorders and other conditions. The drug increases γ-aminobutyric acid (GABA) levels in the brain and has been found to improve sleep, including by increasing slow wave sleep (deep sleep). In addition, tiagabine has been reported to make sleep feel more restorative and to improve some cognitive outcomes. The drug has an elimination half-life of 5 to 8 hours. While tiagabine may have hypnotic effects, off-label use is discouraged as it has been associated with new-onset seizures in people without epilepsy.
== Geonium atom == A geonium atom is a pseudo-atomic system that consists of a single electron or ion stored in a Penning trap which is 'bound' to the remaining Earth, hence the term 'geonium'. The name was coined by H.G. Dehmelt. In the typical case, the trapped system consists of only one particle or ion. Such a quantum system is determined by quantum states of one particle, like in the hydrogen atom. Hydrogen consists of two particles, the nucleus and electron, but the electron motion relative to the nucleus is equivalent to one particle in an external field, see center-of-mass frame. The properties of geonium are different from a typical atom. The charge undergoes cyclotron motion around the trap axis and oscillates along the axis. An inhomogeneous magnetic "bottle field" is applied to measure the quantum properties by the "continuous Stern-Gerlach" technique. Energy levels and g-factor of the particle can be measured with high precision. Van Dyck, et al. explored the magnetic splitting of geonium spectra in 1978 and in 1987 published high-precision measurements of electron and positron g-factors, which constrained the electron radius.
Sources: en.wikipedia.org
== History == Schering-Plough developed loratadine as part of a quest for a potential blockbuster drug: a nonsedating antihistamine. By the time Schering submitted the drug to the U.S. Food and Drug Administration (FDA) for approval, the agency had already approved a competitor's nonsedating antihistamine, terfenadine (trade name Seldane), and, therefore, put loratadine on a lower priority. However, terfenadine had to be removed from the U.S. market by the manufacturer in late 1997 after reports of serious ventricular arrhythmias among those taking the drug. Loratadine was approved by the FDA in 1993. The drug continued to be available only by prescription in the U.S. until it went off patent in 2002. It was then subsequently approved for over-the-counter sales. Once it became an unpatented over-the-counter drug, the price dropped significantly. Schering also developed desloratadine (Clarinex/Aerius), which is an active metabolite of loratadine.
Cheesemaking (or caseiculture) is the art of making cheese. The production of cheese, like many other food preservation processes, allows the nutritional and economic value of a food material, in this case milk, to be preserved in concentrated form. Cheesemaking allows the production of the cheese with diverse flavors and consistencies.
In December 1940, Franz Simon at Oxford wrote his Estimate of the size of an actual separation plant." Simon proposed gaseous diffusion as the best method for uranium isotope separation. On 28 March 1941, Emilio Segré and Glen Seaborg reported on the "strong indications that 239Pu undergoes fission with slow neutrons." This meant chemical separation was an alternative to uranium isotope separation. Instead, a nuclear reactor fueled with ordinary uranium could produce a plutonium isotope as a nuclear explosive substitute for 235U. In May, they demonstrated the cross section of plutonium was 1.7 times that of U235. When plutonium's cross section for fast fission was measured to be ten times that of U238, plutonium became a viable option for a bomb. In October 1941, MAUD released its final report to the U.S. Government. The report stated, "We have now reached the conclusion that it will be possible to make an effective uranium bomb...The material for the first bomb could be ready by the end of 1943..." In November 1941, John Dunning and Eugene T. Booth were able to demonstrate the enrichment of uranium through gaseous barrier diffusion. On 27 November, Bush delivered to third National Academy of Sciences report to Roosevelt. The report, amongst other things, called for parallel development of all isotope-separation systems. On 6 December, Bush and Conant reorganized the Uranium Committee's tasks, with Harold Urey developing gaseous diffusion, Lawrence developing electromagnetic separation, Eger V.
Commercialized as the Model 470A protein sequencer, it allowed scientists to determine partial amino acid sequences of proteins that had not previously been accessible, characterizing new proteins and better understanding their activity, function, and effects in therapeutics. These discoveries had significant ramifications in biology, medicine, and pharmacology. The first automated DNA synthesizer resulted from a collaboration with Marvin H. Caruthers of the University of Colorado Boulder, and was based on Caruthers' work elucidating the chemistry of phosphoramidite oligonucleotide synthesis. Caltech staff scientist Suzanna J. Horvath worked with Hood and Hunkapiller to learn Caruthers' techniques in order to design a prototype that automated the repetitive steps involved in Caruthers' method for DNA synthesis. The resulting prototype was capable of forming short pieces of DNA called oligonucleotides, which could be used in DNA mapping and gene identification. The first commercial phosphoramidite DNA synthesizer was developed from this prototype by Applied Biosystems, who installed the first Model 380A in Caruthers' lab at the University of Colorado in December 1982, before beginning official commercial shipment of the new instrument. Revolutionizing the field of molecular biology, the DNA synthesizer enabled biologists to synthesize DNA fragments for cloning and other genetic manipulations. Molecular biologists were able to produce DNA probes and primers for use in DNA sequencing and mapping, gene cloning, and gene synthesis.
Hydrogen cyanide is a bulk chemical; global production in 2001 was approximately 2.6 million tons. Key derivatives produced from it include adiponitrile, acetone cyanohydrin, sodium cyanide, and cyanuric chloride. Chelating agents are also synthesized from hydrogen cyanide, for example ethylenediaminetetraacetic acid from formaldehyde, ethylenediamine, hydrogen cyanide, and sodium hydroxide. An important industrial route to amino acids is the Strecker synthesis, in which hydrogen cyanide serves as a starting material. A quantitatively important amino acid is methionine, which is produced from acrolein, hydrogen cyanide, and hydrogen sulphide and is used primarily in animal feed.
Sources: en.wikipedia.org
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.
The two share a family name but have different sequences, sizes, and functions. Thymosin beta-4 is a 43-residue peptide associated with actin binding and cell migration. Thymosin alpha-1 is a 28-residue peptide linked mainly to immune signaling.
Thymalfasin is the assigned international nonproprietary name for the synthetic 28-residue peptide. Thymosin alpha-1 is the descriptive research name for the same molecule. Which term appears depends on the context and the regulatory document.
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.